Clinical Trials Logo

Clinical Trial Summary

This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant ascites. All the participants will randomly receive the treatment of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination or convention drugs peritoneal perfusion and systemic therapy combination.


Clinical Trial Description

As a drug carrier, erythrocytes have their own advantages, such as high biocompatibility, high immune compatibility, simple structure and easy access. In this study, microparticles released from erythrocytes are used as the carrier of chemotherapy drugs and effectively kill tumor cells in malignant ascites. These microparticles can easily reach the tumor site and bring the drug into tumor cells, which can overcome the two main problems in normal chemotherapy: damage to normal cells and drug resistance of tumor cells. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03230708
Study type Interventional
Source Hubei Cancer Hospital
Contact Hui ting Xu
Phone 15307176219
Email 2891533@qq.com
Status Recruiting
Phase Phase 1/Phase 2
Start date May 1, 2017
Completion date February 1, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06200376 - A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer Phase 1
Completed NCT04051112 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites Phase 1
Completed NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Phase 2/Phase 3
Not yet recruiting NCT05501340 - PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Phase 1/Phase 2
Not yet recruiting NCT03550560 - EUS-Guided Drainage of Refractory Malignant Ascites
Recruiting NCT04501744 - A Study of M701 (EpCAM and CD3) in Malignant Ascites Phase 1
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT05477927 - Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases Phase 1
Active, not recruiting NCT06266091 - Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody Phase 2
Withdrawn NCT04076566 - Malignant Ascites Alfapump® Study
Enrolling by invitation NCT01854866 - Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion Phase 2
Completed NCT01327235 - Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase 2
Recruiting NCT06432296 - Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Terminated NCT02496286 - Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Phase 1
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT00326885 - Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase 2
Recruiting NCT02530398 - A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Phase 1
Withdrawn NCT00908219 - A Study of Bevacizumab to Prevent Malignant Ascites Phase 2
Recruiting NCT06016179 - Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Phase 1